Myovant Sciences

Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie
Fierce Pharma
Wed, 05/26/21 - 11:58 pm
Myovant Sciences
Pfizer
FDA
Relugolix
uterine fibroids
Corporate and regulatory developments over the holidays
EP Vantage
Mon, 01/4/21 - 10:20 am
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab
In groundbreaking move, FDA approves Myovant's relugolix as the first once-a-day pill for advanced prostate cancer
Endpoints
Sat, 12/19/20 - 11:24 pm
Myovant Sciences
Relugolix
FDA
prostate cancer
Orgovyx
Myovant Squares Off with AbbVie On Endometriosis Treatment
Motley Fool
Sun, 04/26/20 - 01:49 pm
Myovant Sciences
AbbVie
endometriosis
Relugolix
Orilissa
clinical trials
Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study
Motley Fool
Mon, 02/10/20 - 11:27 pm
Myovant Sciences
Relugolix
uterine fibroids
clinical trials
Is Myovant's New Prostate Cancer Drug a Game Changer?
Motley Fool
Tue, 11/26/19 - 10:33 am
Myovant Sciences
prostate cancer
clinical trials
Relugolix
Myovant to submit lead drug for prostate cancer approval after Phase 3 results
Biopharma Dive
Tue, 11/19/19 - 10:12 am
Myovant Sciences
prostate cancer
clinical trials
Relugolix
Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown
Fierce Biotech
Tue, 05/14/19 - 09:26 am
Myovant Sciences
Relugolix
clinical trials
uterine fibroids
AbbVie
Elagolix
Drugmakers revive R&D focus on long stagnant women's health market
Medical Marketing and Media
Tue, 08/23/16 - 10:50 am
R&D
Women's Health
innovation
Myovant Sciences
Amgen
UCB Pharma
breast cancer
Pfizer
S1 Biopharma
Ibrance
Addyi